In vivo experiments using subcutaneous and intraperitoneal SKOV-3 models further confirmed that ATG9A ablation enhances macrophage-mediated killing of cancer cells, suggesting that targeting ATG9A may improve responses to macrophage-based therapies. This evidence concerns the gene ATG9A and cancer.